more

Myovant Sciences Ltd. (MYOV)

(Delayed Data from NYSE)

$17.72 USD

+0.07 (0.40%)

Updated May 3, 2019 04:01 PM ET

After-Market: $17.69 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Dec 29, 2020

by Zacks Equity Research Published on December 29,2020

Companies In The News Are: TSLA, LMT, MYOV, PFE, DASH

Is the Options Market Predicting a Spike in Myovant Sciences (MYOV) Stock?

by Zacks Equity Research Published on December 16,2020

Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.

MYOVPositive Net Change

medical

Biotech Stock Roundup: REGN's Cocktail Data, GILD's RA Drug Approval & Other Updates

by Zacks Equity Research Published on October 01,2020

The biotech sector remains in focus with regulatory and other pipeline updates.

Is the Options Market Predicting a Spike in Myovant Sciences (MYOV) Stock?

by Zacks Equity Research Published on September 25,2020

Investors need to pay close attention to Myovant Sciences (MYOV) stock based on the movements in the options market lately.

MYOVPositive Net Change

medical

Myovant's Endometriosis Pain Drug Meets Goal in Study, Stock Up

by Zacks Equity Research Published on June 24,2020

Myovant (MYOV) reports positive top-line data from the phase III study on the relugolix combination therapy in women suffering from pain associated with endometriosis.

biotechs

Company News for Jun 24, 2020

by Zacks Equity Research Published on June 24,2020

Companies In The News Are: SPR, BA, EA, TBIO, SNY, MYOV.

Worried About a Weak Dollar? Here's How to Trade & Win

by Sanghamitra Saha Published on June 11,2020

The ultra-easy Fed policy and widening U.S. deficit are likely to keep the greenback subdued in this coming days.

tech-stocks

Myovant Eyes Relugolix Combo Approval for Uterine Fibroids

by Zacks Equity Research Published on June 02,2020

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix combination regimen as a treatment for heavy menstrual bleeding associated with uterine fibroids.

biotechs

Do Options Traders Know Something About Myovant (MYOV) Stock We Don't?

by Zacks Equity Research Published on June 02,2020

Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.

MYOVPositive Net Change

Company News for June 2, 2020

by Zacks Equity Research Published on June 02,2020

Companies in the news are: MYOV, ITRM, COTY, OPK

Myovant Eyes Relugolix Approval for Advanced Prostate Cancer

by Zacks Equity Research Published on April 22,2020

Myovant (MYOV) submits a regulatory application with the FDA seeking approval for oral relugolix as a treatment for advanced prostate cancer.

biotechs

Myovant Sciences (MYOV) Jumps: Stock Rises 8.3%

by Zacks Equity Research Published on April 15,2020

Myovant Sciences (MYOV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Why Myovant Sciences (MYOV) Stock Might be a Great Pick

by Zacks Equity Research Published on April 09,2020

Myovant Sciences (MYOV) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

MYOVPositive Net Change

medical

Is the Options Market Predicting a Spike in Myovant (MYOV) Stock?

by Zacks Equity Research Published on February 21,2020

Investors need to pay close attention to Myovant (MYOV) stock based on the movements in the options market lately.

MYOVPositive Net Change

medical

Biotech Tops in November: Best ETFs & Stocks

by Sweta Killa Published on November 29,2019

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.